RATIONALE: Currently available antidepressants upregulate hippocampal neurogenesis and prefrontal gliogenesis after chronic administration, which could block or reverse the effects of stress. Allosteric alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor potentiators (ARPs), which have novel targets compared to current antidepressants, have been shown to have antidepressant properties in neurogenic and behavioral models. OBJECTIVES: This study analyzed the effect of the ARP Org 26576 on the proliferation, survival, and differentiation of neurons and glia in the hippocampus and prelimbic cortex of adult rats. MATERIALS AND METHODS: Male Sprague-Dawley rats received acute (single day) or chronic (21 day) twice-daily intraperitoneal injections of Org 26576 (1-10 mg/kg). Bromodeoxyuridine (BrdU) immunohistochemistry was conducted 24 h or 28 days after the last drug injection for the analysis of cell proliferation or survival, respectively. Confocal immunofluorescence analysis was used to determine the phenotype of surviving cells. RESULTS: Acute administration of Org 26576 did not increase neuronal cell proliferation. However, chronic administration of Org 26576 increased progenitor cell proliferation in dentate gyrus (approximately 40%) and in prelimbic cortex (approximately 35%) at the 10-mg/kg dosage. Cells born in response to chronic Org 26576 in dentate gyrus exhibited increased rates of survival (approximately 30%) with the majority of surviving cells expressing a neuronal phenotype. CONCLUSION: Findings suggest that Org 26576 may have antidepressant properties, which may be attributed, in part, to upregulation of hippocampal neurogenesis and prelimbic cell proliferation.
RATIONALE: Currently available antidepressants upregulate hippocampal neurogenesis and prefrontal gliogenesis after chronic administration, which could block or reverse the effects of stress. Allosteric alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor potentiators (ARPs), which have novel targets compared to current antidepressants, have been shown to have antidepressant properties in neurogenic and behavioral models. OBJECTIVES: This study analyzed the effect of the ARP Org 26576 on the proliferation, survival, and differentiation of neurons and glia in the hippocampus and prelimbic cortex of adult rats. MATERIALS AND METHODS: Male Sprague-Dawley rats received acute (single day) or chronic (21 day) twice-daily intraperitoneal injections of Org 26576 (1-10 mg/kg). Bromodeoxyuridine (BrdU) immunohistochemistry was conducted 24 h or 28 days after the last drug injection for the analysis of cell proliferation or survival, respectively. Confocal immunofluorescence analysis was used to determine the phenotype of surviving cells. RESULTS: Acute administration of Org 26576 did not increase neuronal cell proliferation. However, chronic administration of Org 26576 increased progenitor cell proliferation in dentate gyrus (approximately 40%) and in prelimbic cortex (approximately 35%) at the 10-mg/kg dosage. Cells born in response to chronic Org 26576 in dentate gyrus exhibited increased rates of survival (approximately 30%) with the majority of surviving cells expressing a neuronal phenotype. CONCLUSION: Findings suggest that Org 26576 may have antidepressant properties, which may be attributed, in part, to upregulation of hippocampal neurogenesis and prelimbic cell proliferation.
Authors: Graeme R Jordan; James McCulloch; Mohammed Shahid; David R Hill; Brian Henry; Karen Horsburgh Journal: Neuropharmacology Date: 2005-08 Impact factor: 5.250
Authors: Ronald C Kessler; Patricia Berglund; Olga Demler; Robert Jin; Doreen Koretz; Kathleen R Merikangas; A John Rush; Ellen E Walters; Philip S Wang Journal: JAMA Date: 2003-06-18 Impact factor: 56.272
Authors: Sungho Maeng; Carlos A Zarate; Jing Du; Robert J Schloesser; Joseph McCammon; Guang Chen; Husseini K Manji Journal: Biol Psychiatry Date: 2007-07-23 Impact factor: 13.382
Authors: Mounira Banasr; Gerald W Valentine; Xiao-Yuan Li; Shannon L Gourley; Jane R Taylor; Ronald S Duman Journal: Biol Psychiatry Date: 2007-06-21 Impact factor: 13.382
Authors: Marzena Mackowiak; Michael J O'Neill; Caroline A Hicks; David Bleakman; Phil Skolnick Journal: Neuropharmacology Date: 2002-07 Impact factor: 5.250
Authors: Kent Jardemark; Monica M Marcus; Anna Malmerfelt; Mohammed Shahid; Torgny H Svensson Journal: Psychopharmacology (Berl) Date: 2011-11-09 Impact factor: 4.530
Authors: Roberta Bursi; Gul Erdemli; Robert Campbell; Matthew M Hutmacher; Thomas Kerbusch; David Spanswick; Ross Jeggo; Kari R Nations; Peter Dogterom; Jacques Schipper; Mohammed Shahid Journal: Psychopharmacology (Berl) Date: 2011-06-07 Impact factor: 4.530
Authors: Tri Indah Winarni; Weerasak Chonchaiya; Evan Adams; Jacky Au; Yi Mu; Susan M Rivera; Danh V Nguyen; Randi J Hagerman Journal: Autism Res Treat Date: 2012-05-31
Authors: Bashkim Kadriu; Laura Musazzi; Jenessa N Johnston; Lisa E Kalynchuk; Hector J Caruncho; Maurizio Popoli; Carlos A Zarate Journal: Drug Discov Today Date: 2021-08-03 Impact factor: 8.369
Authors: Max Nordgren; Tobias Karlsson; Maria Svensson; Josefin Koczy; Anna Josephson; Lars Olson; Anders Tingström; Stefan Brené Journal: PLoS One Date: 2013-11-14 Impact factor: 3.240